Evidence map›Paper›PMID 36668835›Full record

ArticleToxins2022

Monoclonal-Based Antivenomics Reveals Conserved Neutralizing Epitopes in Type I PLA

Carlos Corrêa-Netto, Marcelo A Strauch, Marcos Monteiro-Machado, Ricardo Teixeira-Araújo, Juliana Guzzo Fonseca, Moema Leitão-Araújo, Maria Lúcia Machado-Alves, Libia Sanz, Juan J Calvete, Paulo A Melo and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Conserved Enzymatic Peptides inInternational journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Carlos Corrêa-NettoInstituto Vital Brazil, Rio de Janeiro 24230-410, RJ, Brazil.ORCID 0000-0003-2022-0222
Marcelo A StrauchInstituto Vital Brazil, Rio de Janeiro 24230-410, RJ, Brazil.ORCID 0000-0002-9576-6310
Marcos Monteiro-MachadoPrograma de Farmacologia e Química Medicinal-UFRJ, Instituto de Ciências Biomédicas, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho, 373, Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0002-1657-1356
Ricardo Teixeira-AraújoInstituto Vital Brazil, Rio de Janeiro 24230-410, RJ, Brazil.
Juliana Guzzo FonsecaInstituto Vital Brazil, Rio de Janeiro 24230-410, RJ, Brazil.
Moema Leitão-AraújoFundação Zoobotânica do Rio Grande do Sul, Museu de Ciências Naturais, Núcleo Regional de Ofiologia de Porto Alegre, Porto Alegre 90690-000, RS, Brazil.
Maria Lúcia Machado-AlvesFundação Zoobotânica do Rio Grande do Sul, Museu de Ciências Naturais, Núcleo Regional de Ofiologia de Porto Alegre, Porto Alegre 90690-000, RS, Brazil.
Libia SanzLaboratorio de Venómica Estructural y Funcional, Instituto de Biomedicina de Valencia, 46010 Valencia, Spain.
Juan J CalveteLaboratorio de Venómica Estructural y Funcional, Instituto de Biomedicina de Valencia, 46010 Valencia, Spain.ORCID 0000-0001-5026-3122
Paulo A MeloPrograma de Farmacologia e Química Medicinal-UFRJ, Instituto de Ciências Biomédicas, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho, 373, Rio de Janeiro 21941-902, RJ, Brazil.
Russolina Benedeta ZingaliInstituto de Bioquímica Médica Leopoldo de Meis, Instituto Nacional de Biologia Estrutural e Bioimagem, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0003-3156-6923
Universidade Federal do Rio de Janeiro · BRInstituto de Biomedicina de Valencia · ESMuseu de Ciências Naturais da Fundação Zoobotânica do Rio Grande do Sul · BRInstituto Vital Brazil (Brazil) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For over a century, polyclonal antibodies have been used to treat snakebite envenoming and are still considered by the WHO as the only scientifically validated treatment for snakebites. Nevertheless, moderate innovations have been introduced to this immunotherapy. New strategies and approaches to understanding how antibodies recognize and neutralize snake toxins represent a challenge for next-generation antivenoms. The neurotoxic activity of

Indexed as

Coral SnakesSnake BitesAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntiveninsElapidaeElapid VenomsEpitopesPhospholipases A2Antibodies, MonoclonalAntibodies, NeutralizingAntiveninsElapid VenomsEpitopesPhospholipases A2enzymatic activitymonoclonal antibodymyotoxicityneutralization PLA2 activityphospholipase A2

Identifiers

PMID36668835
PMCPMC9863321
OpenAlexW4313244231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.